Clinical Trial Update: Dose-escalation Study of LTX-315 in Patients With a Transdermally Accessible Tumour [Phase 1]

View source ↗

Summary

This entry communicates the completion of a Phase 1 dose-escalation trial of LTX-315 in patients with transdermally accessible tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• LTX-315 (LTX-315 peptide)

Snippet

Sponsor: Lytix Biopharma AS | Conditions: Cancer With Transdermal Accessible Tumour | Phase 1 | Status: COMPLETED